Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

  • Sci Rep. 2022 Nov 4;12(1):18731. doi: 10.1038/s41598-022-23619-6.
Jun Gong  1 ,  Shant Thomassian  1 ,  Sungjin Kim  1 ,  Gillian Gresham  1 ,  Natalie Moshayedi  1 ,  Jason Y Ye  2 ,  Julianne C Yang  2 ,  Jonathan P Jacobs  2 ,  Simon Lo  1 ,  Nick Nissen  1 ,  Srinivas Gaddam  1 ,  Mourad Tighiouart  1 ,  Arsen Osipov  1 ,  Andrew Hendifar  3
Affiliations
  • 1. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
  • 2. The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
  • 3. Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. [email protected].
PMID: 36333397 DOI: 10.1038/s41598-022-23619-6
Products